Wavegate Corporation, a neuromodulation technology company specializing in chronic pain management, has raised $26 million in a Series A funding round led by UCEA Capital Partners Ltd.
Based in Louisiana, Wavegate offers the Ellipse Spinal Cord Stimulator Platform to treat chronic pain. The platform features its patented, FDA-cleared StimuLux technology, which leverages optical reflectometry to monitor the spinal cord and deliver closed-loop adaptive modulation. This ensures a consistent electrical current, even as body movements occur.
The new funds will accelerate the development of the Ellipse platform, including expanding research and development, advancing clinical trials, and preparing for regulatory approval.
"Securing this funding marks a critical milestone for Wavegate as we push the limits of neuromodulation technology," said Dr. Erich Wolf, CEO of Wavegate Corporation. "UCEA's investment underscores the promise of our innovations and supports our mission to deliver effective, patient-focused pain management solutions."
Click here to read the original news story.